Overview
NICE is unable to recommend panitumumab with 5‑fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults. This is because Amgen did not provide an evidence submission.
We have published technology appraisal guidance on cetuximab and panitumumab for previously untreated metastatic colorectal cancer.
Last reviewed: 29 March 2017
The population covered by the marketing authorisation for panitumumab changed from ‘patients with wild-type KRAS metastatic colorectal cancer’ to ‘patients with wild-type RAS metastatic colorectal cancer’.
Next review: We will review this decision if the company decides to make a submission.